Literature DB >> 15374367

Effects of idebenone in elderly subjects with cognitive decline. Results of a multicentre clinical trial.

B Bergamasco1, C Villardita, R Coppi.   

Abstract

A randomized, multicentre study on idebenone vs. oxiracetam was carried out in order to evaluate the therapeutic efficacy of idebenone in subjects with senile cognitive decline. Seventy-nine patients were enrolled: 39 treated with idebenone 45 mg twice daily p.o. and 40 treated with oxiracetam 800 mg twice daily p.o. Idebenone proved to be more effective and was shown to be statistically significant in the following test: SCAG, Rey's 15 Words, Gottfries Rating Scale. The greater efficacy of idebenone was confirmed by the efficacy judgement given by the investigators. The tolerability of both treatments can be said to be most satisfactory: none of the patients left the study because of side-effects. No significant variations were observed in the vital signs.

Entities:  

Year:  1992        PMID: 15374367     DOI: 10.1016/0167-4943(92)90063-a

Source DB:  PubMed          Journal:  Arch Gerontol Geriatr        ISSN: 0167-4943            Impact factor:   3.250


  3 in total

1.  Use of Noben (idebenone) in the treatment of dementia and memory impairments without dementia.

Authors:  K V Voronkova; M N Meleshkov
Journal:  Neurosci Behav Physiol       Date:  2009-06

Review 2.  Idebenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in age-related cognitive disorders.

Authors:  J C Gillis; P Benefield; D McTavish
Journal:  Drugs Aging       Date:  1994-08       Impact factor: 3.923

3.  Efficacy of idebenone in the Treatment of iRBD into Synucleinopathies (EITRS): rationale, design, and methodology of a randomized, double-blind, multi-center clinical study.

Authors:  Yuanyuan Li; Chunyi Wang; Ningdi Luo; Fangzheng Chen; Liche Zhou; Mengyue Niu; Wenyan Kang; Jun Liu
Journal:  Front Neurol       Date:  2022-09-12       Impact factor: 4.086

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.